France
Dianosic, founded in 2017, operates at the intersection of Biotechnology, Medical Devices, and Pharmaceutical industries. Headquartered in France, the company is embroiled in revolutionizing patient adherence to medication through its innovative sustained intranasal drug delivery solutions, targeting respiratory and chronic central nervous system diseases.
Dianosic's mission is to alleviate chronic diseases, beginning with chronic allergic rhinitis and rhinosinusitis, where compliance and treatment effectiveness are major concerns for over 85% and up to 25% of patients, respectively. Their collaboration with healthcare specialists in otorhinolaryngology and neurosurgery fosters solutions that enhance treatment efficacy and ease-of-use for patients and physicians alike.
Their flagship platform, ARIS, utilizes a proprietary drug-eluting, long-term resorbable polymer, encapsulating its motto, "Smartly designed for you," by offering "insert and forget" solutions. Their recent €4.70M Seed Round investment round, backed by Bpifrance, Fondation Force, and WiSEED, underscores investor confidence in their trajectory.
